Compare HGLB & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HGLB | BNR |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.7M | 233.7M |
| IPO Year | N/A | 2020 |
| Metric | HGLB | BNR |
|---|---|---|
| Price | $9.52 | $19.76 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 91.8K | 59.8K |
| Earning Date | 01-01-0001 | 11-20-2025 |
| Dividend Yield | ★ 13.16% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $75,749,382.00 |
| Revenue This Year | N/A | $136.32 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 5.56 |
| 52 Week Low | $6.42 | $2.18 |
| 52 Week High | $9.45 | $23.59 |
| Indicator | HGLB | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 46.36 | 61.34 |
| Support Level | $9.46 | $17.66 |
| Resistance Level | $10.11 | $23.59 |
| Average True Range (ATR) | 0.31 | 2.75 |
| MACD | 0.01 | 0.33 |
| Stochastic Oscillator | 55.19 | 68.06 |
Highland Global Allocation Fund is a diversified, closed-end management investment company. The investment objective of the Fund is to seek long-term growth of capital and future income. The Fund seeks to achieve its investment objectives by investing in a portfolio of U.S. and foreign equity, debt, and money market securities. It may also invest in senior loans to domestic or foreign corporations, partnerships, and other entities that operate in a variety of industries and geographic regions.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.